Where is support for this stock once buying at 15c is filled?, page-9

I held BNO until BNC210 failed in PTSD trials, I keep a watching brief. I currently hold SPL (Starpharma) which has a large program of drug development. One about to be released for sale and with an FDA decision pending, two in clinical trials and a range in pre-clinical trials and R&D.

It surprises me that BNO is spending $8.25M on R&D during the quarter when SPL is spending a quarter of this amount on what appears to be a bigger program. Staff and admin costs for SPL are $2M as opposed to $1.5M for BNO.

Revenues are about the same at $2M.

With work stopping on BNC210 for the next few months I would expect a very serious reduction in R&D simply because they cannot afford to do anything else and keep the company afloat.

And Deborah cannot afford to pocket her pay when there is so little going on. She must cut herself and some of her colleagues. When things fail the staff have to share the pain of the shareholders!